FDA Clears OncoMate MSI Dx for Pembrolizumab in MSI-H Solid Tumors

The U.S. FDA has approved the OncoMate MSI Dx Analysis System as a companion diagnostic. This system identifies patients with microsatellite instability–high (MSI-H) solid tumors who are eligible for treatment with the anti–PD-1 therapy pembrolizumab (Keytruda). This approval, based on a Promega Corporation news release, expands precision medicine options for cancer patients.